← Browse by Condition
Medical Condition
hormone sensitive prostate cancer
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3
NCT06473259
Recruiting
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Enrollment
3,000 pts
Location
Italy
Sponsor
Santa Chiara Hospital
NCT07028853 Phase 3
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Enrollment
1,000 pts
Location
United States, Argen...
Sponsor
Pfizer